Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

Niraparib is an investigational oral, once daily, selective poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor. In the pivotal Phase 3 NOVA/ENGOT/OV16 study, niraparib met its primary endpoint of improving progression-free survival (PFS) for adult patients with recurrent, platinum sensitive,...

Descripción completa

Detalles Bibliográficos
Autores principales: van Andel, Lotte, Zhang, Z., Lu, S., Kansra, V., Agarwal, S., Hughes, L., Tibben, M. M., Gebretensae, A., Lucas, L., Hillebrand, M. J. X., Rosing, H., Schellens, J. H. M., Beijnen, J. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694528/
https://www.ncbi.nlm.nih.gov/pubmed/28303528
http://dx.doi.org/10.1007/s10637-017-0451-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694528/
https://www.ncbi.nlm.nih.gov/pubmed/28303528
http://dx.doi.org/10.1007/s10637-017-0451-2

Ejemplares similares